HS-110 + erlotinib

**HS-110 + erlotinib** is an investigational combination therapy comprising HS-110 (a cell-based therapeutic cancer vaccine) administered with erlotinib (a small-molecule tyrosine kinase inhibitor). HS-110 is an allogeneic, off-the-shelf tumor cell vaccine designed to induce T-cell mediated antitumor immunity, primarily targeting lung cancer antigens. Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), acting by inhibiting EGFR-mediated signaling that drives tumor cell proliferation. The combination aims to enhance immune response while blocking EGFR-driven tumor cell survival pathways. Investigational trials have evaluated safety, tolerability, and immunologic activity of this regimen in advanced NSCLC[1].

Other names

HS-110 plus erlotinibHS110 plus erlotinibHS 110 plus erlotinibHS-110 and erlotinibHS110 and erlotinibHS 110 and erlotinib